Dergiler / Eskisehir Medical Journal / 2022 / Cilt: 3 - Sayı: 3

İkinci doz Pfizer-BioNTech COVID-19 messenger RNA sonrası gelişen Eritema Nodozum olgusu

Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report

Sayfa
322–323
Yayın Tarihi
2022-11-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies.
📊
Temel Bulgular & Veri:The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1].
💡
Sonuç & Katkı:We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Eritema Nodosum · messenger RNA aşısı · Erythema Nodosum

Özet

Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies. The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1]. EN is characterized clinically by painful tender, nodular, erythematous lesions, typically symmetrically on pretibial surfaces. The occurrence of EN after vaccination is rare and especially post-covid vaccine limited number in the literature. We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

Abstract

Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies. The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1]. EN is characterized clinically by painful tender, nodular, erythematous lesions, typically symmetrically on pretibial surfaces. The occurrence of EN after vaccination is rare and especially post-covid vaccine limited number in the literature. We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

🔖

Bu Makaleye Atıf Yap

BODAKÇİ, E. (2022). İkinci doz Pfizer-BioNTech COVID-19 messenger RNA sonrası gelişen Eritema Nodozum olgusu. Eskisehir Medical Journal, Cilt: 3 - Sayı: 3, 322–323. https://ajindex.com/articles/873382

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Leung AKC, Leong KF, Lam JM. Erythema nodosum.World J Pediatr2018
  2. 548–554 2. Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg. 2007
  3. 26(2):114–25. https://doi.org/10.1016/j. Sder.2007.02.009. 3. De Simone C, Caldarola G, Scaldaferri F, Petito V, Perino F, Arena V, et al. Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. Int J Dermatol. 2016
  4. 55(5):e289–94. https://doi.org/10.1111/ ijd.13212 4. Cohen PR. Combined reduced-antigen content tetanus, diphtheria,and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.DermatolTher (Heidelb). 2013
  5. 3(2):191-197. 5. Teymour S, Ahram A, Blackwell T, Bhate C, Cohen PJ, Whitworth JM. Erythema nodosum after Moderna mRNA-1273 COVID-19 vaccine. Dermatol Ther. 2022 Jan 4:e15302. doi: 10.1111/dth.15302. Epub ahead of print. PMID: 34984777. 6. Aly MH, Alshehri AA, Mohammed A, Almalki AM, Ahmed WA,Almuflihi AM, et al. First case of erythema nodosum associated with Pfizer vaccine.Cureus. 2021
  6. 13(11):e19529. doi:10.7759/cureus.19529 7. Wu X, Lim JHL, Lee JSS, Chio MT. Recurrent erythema nodosumafter the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine.JAAD Int. 2022
  7. doi:10.1016/j.jdin.2021.12.009 8. Dameska, Katerina
  8. Simeonovskı, Viktor. Covid‐19 Vaccine Associated Erythema Nodosum: factors to consider. Dermatologic Therapy, 2022, e15410.